Ocugen, Inc. - Common Stock (OCGN)

A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism.

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options.

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

OCGN earnings call for the period ending December 31, 2024.

OCGN earnings call for the period ending September 30, 2024.

OCGN earnings call for the period ending June 30, 2024.